NAS
AUPH icon

Nykredit A/S’s Aurinia Pharmaceuticals AUPH Stock Holding History

Nykredit A/S’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.3K Buy
+2,082
New +$33.3K ﹤0.01% 1579

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nykredit A/S's AUPH Position: Q2 2026 in Review

Nykredit A/S opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 2,082 shares worth $35.3K. The stake represents ﹤0.01% of the portfolio and ranks #1579 among its holdings.

205 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Nykredit A/S held 2,082 shares of Aurinia Pharmaceuticals worth $35.3K as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1579 holding.
  • 205 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.